|
1
|
Sanyal AJ, Campbell-Sargent C, Mirshahi F,
Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML and Clore
JN: Nonalcoholic steatohepatitis: association of insulin resistance
and mitochondrial abnormalities. Gastroenterology. 120:1183–1192.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanyal AJ: American Gastroenterological
Association: AGA technical review on nonalcoholic fatty liver
disease. Gastroenterology. 123:1705–1725. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Day CP: Pathogenesis of steatohepatitis.
Best Pract Res Clin Gastroenterol. 16:663–678. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Browning JD, Szczepaniak LS, Dobbins R,
Nuremberg P, Horton JD, Cohen JC, Grundy SM and Hobbs HH:
Prevalence of hepatic steatosis in an urban population in the
United States: impact of ethnicity. Hepatology. 40:1387–1395. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gaggini M, Morelli M, Buzzigoli E,
DeFronzo RA, Bugianesi E and Gastaldelli A: Non-alcoholic fatty
liver disease (NAFLD) and its connection with insulin resistance,
dyslipidemia, atherosclerosis and coronary heart disease.
Nutrients. 5:1544–1560. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Williams CD, Stengel J, Asike MI, Torres
DM, Shaw J, Contreras M, Landt CL and Harrison SA: Prevalence of
nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
among a largely middle-aged population utilizing ultrasound and
liver biopsy: a prospective study. Gastroenterology. 140:124–131.
2011. View Article : Google Scholar
|
|
7
|
Yki-Jarvinen H: Liver fat in the
pathogenesis of insulin resistance and type 2 diabetes. Dig Dis.
28:203–209. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fabbrini E, Magkos F, Mohammed BS, Pietka
T, Abumrad NA, Patterson BW, Okunade A and Klein S: Intrahepatic
fat, not visceral fat, is linked with metabolic complications of
obesity. Proc Natl Acad Sci USA. 106:15430–15435. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yki-Jarvinen H: Fat in the liver and
insulin resistance. Ann Med. 37:347–356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Desvergne B and Wahli W: Peroxisome
proliferator-activated receptors: nuclear control of metabolism.
Endocr Rev. 20:649–688. 1999.PubMed/NCBI
|
|
11
|
Aoyama T, Peters JM, Iritani N, Nakajima
T, Furihata K, Hashimoto T and Gonzalez FJ: Altered constitutive
expression of fatty acid-metabolizing enzymes in mice lacking the
peroxisome proliferator-activated receptor alpha (PPARalpha). J
Biol Chem. 273:5678–5684. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fan CY, Pan J, Chu R, Lee D, Kluckman KD,
Usuda N, Singh I, Yeldandi AV, Rao MS, Maeda N and Reddy JK:
Hepatocellular and hepatic peroxisomal alterations in mice with a
disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J Biol
Chem. 271:24698–24710. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leone TC, Weinheimer CJ and Kelly DP: A
critical role for the peroxisome proliferator-activated receptor
alpha (PPARalpha) in the cellular fasting response: the
PPARalpha-null mouse as a model of fatty acid oxidation disorders.
Proc Natl Acad Sci USA. 96:7473–7478. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tontonoz P, Hu E and Spiegelman BM:
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a
lipid-activated transcription factor. Cell. 79:1147–1156. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Larsen TM, Toubro S and Astrup A:
PPARgamma agonists in the treatment of type II diabetes: is
increased fatness commensurate with long-term efficacy? Int J Obes
Relat Metab Disord. 27:147–161. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seo YS, Kim JH, Jo NY, Choi KM, Baik SH,
Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, et al: PPAR agonists
treatment is effective in a nonalcoholic fatty liver disease animal
model by modulating fatty-acid metabolic enzymes. J Gastroenterol
Hepatol. 23:102–109. 2008.PubMed/NCBI
|
|
17
|
Gillies PS and Dunn CJ: Pioglitazone.
Drugs. 60:333–345. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smith U: Pioglitazone: mechanism of
action. Int J Clin Pract. (Suppl): 13–18. 2001.
|
|
19
|
Vamecq J and Latruffe N: Medical
significance of peroxisome proliferator-activated receptors.
Lancet. 354:141–148. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Neuschwander-Tetri BA, Brunt EM, Wehmeier
KR, Oliver D and Bacon BR: Improved nonalcoholic steatohepatitis
after 48 weeks of treatment with the PPAR-gamma ligand
rosiglitazone. Hepatology. 38:1008–1017. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oger F, Dubois-Chevalier J, Gheeraert C,
Avner S, Durand E, Froguel P, Salbert G, Staels B, Lefebvre P and
Eeckhoute J: Peroxisome proliferator-activated receptor gamma
regulates genes involved in insulin/insulin-like growth factor
signaling and lipid metabolism during adipogenesis through
functionally distinct enhancer classes. J Biol Chem. 289:708–722.
2014. View Article : Google Scholar :
|
|
22
|
Coll T, Alvarez-Guardia D, Barroso E,
Gómez-Foix AM, Palomer X, Laguna JC and Vázquez-Carrera M:
Activation of peroxisome proliferator-activated receptor-{delta} by
GW501516 prevents fatty acid-induced nuclear factor-{kappa}B
activation and insulin resistance in skeletal muscle cells.
Endocrinology. 151:1560–1569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barroso E, Rodriguez-Calvo R,
Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X and
Vázquez-Carrera M: The PPARbeta/delta activator GW501516 prevents
the down-regulation of AMPK caused by a high-fat diet in liver and
amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to
increased fatty acid oxidation. Endocrinology. 152:1848–1859. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Serrano-Marco L, Barroso E, El Kochairi I,
Palomer X, Michalik L, Wahli W and Vázquez-Carrera M: The
peroxi-some proliferator-activated receptor (PPAR) beta/delta
agonist GW501516 inhibits IL-6-induced signal transducer and
activator of transcription 3 (STAT3) activation and insulin
resistance in human liver cells. Diabetologia. 55:743–751. 2012.
View Article : Google Scholar
|
|
25
|
Nagasawa T, Inada Y, Nakano S, Tamura T,
Takahashi T, Maruyama K, Yamazaki Y, Kuroda J and Shibata N:
Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta
agonist, on development of steatohepatitis in mice fed a
methionine- and choline-deficient diet. Eur J Pharmacol.
536:182–191. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment:
insulin resistance and beta-cell function from fasting plasma
glucose and insulin concentrations in man. Diabetologia.
28:412–419. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang HN, Wang YR, Liu GQ, Liu Z, Wu PX,
Wei XL and Hong TP: Inhibition of hepatic interleukin-18 production
by rosiglitazone in a rat model of nonalcoholic fatty liver
disease. World J Gastroenterol. 14:7240–7246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
29
|
Ferre P and Foufelle F: Hepatic steatosis:
a role for de novo lipo-genesis and the transcription factor
SREBP-1c. Diabetes Obes Metab. 12(Suppl 2): S83–S92. 2010.
View Article : Google Scholar
|
|
30
|
Shimano H, Yahagi N, Amemiya-Kudo M, Hasty
AH, Osuga J, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, Harada K,
et al: Sterol regulatory element-binding protein-1 as a key
transcription factor for nutritional induction of lipogenic enzyme
genes. J Biol Chem. 274:35832–35839. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Keller H, Dreyer C, Medin J, Mahfoudi A,
Ozato K and Wahli W: Fatty acids and retinoids control lipid
metabolism through activation of peroxisome proliferator-activated
receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA.
90:2160–2164. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Keller H, Mahfoudi A, Dreyer C, Hihi AK,
Medin J, Ozato K and Wahli W: Peroxisome proliferator-activated
receptors and lipid metabolism. Ann NY Acad Sci. 684:157–173. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Keller H and Wahli W: Peroxisome
proliferator-activated receptors A link between endocrinology and
nutrition? Trends Endocrinol Metab. 4:291–296. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kliewer SA, Sundseth SS, Jones SA, Brown
PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard
JM and Lehmann JM: Fatty acids and eicosanoids regulate gene
expression through direct interactions with peroxisome
prolif-erator-activated receptors alpha and gamma. Proc Natl Acad
Sci USA. 94:4318–4323. 1997. View Article : Google Scholar
|
|
35
|
Forman BM, Chen J and Evans RM:
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids
are ligands for peroxisome proliferator-activated receptors alpha
and delta. Proc Natl Acad Sci USA. 94:4312–4317. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee CH, Olson P, Hevener A, Mehl I, Chong
LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM and Evans RM:
PPARdelta regulates glucose metabolism and insulin sensitivity.
Proc Natl Acad Sci USA. 103:3444–3449. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cases S, Smith SJ, Zheng YW, Myers HM,
Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusis AJ, et al:
Identification of a gene encoding an acyl CoA: diacylglycerol
acyltransferase, a key enzyme in triacylglycerol synthesis. Proc
Natl Acad Sci USA. 95:13018–13023. 1998. View Article : Google Scholar
|
|
38
|
Eaton S: Control of mitochondrial
beta-oxidation flux. Prog Lipid Res. 41:197–239. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Poirier Y, Antonenkov VD, Glumoff T and
Hiltunen JK: Peroxisomal beta-oxidation - a metabolic pathway with
multiple functions. Biochim Biophys Acta. 1763:1413–1426. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Koo SH: Nonalcoholic fatty liver disease:
molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol.
19:210–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tailleux A, Wouters K and Staels B: Roles
of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys
Acta. 1821:809–818. 2012. View Article : Google Scholar
|
|
42
|
Wahli W and Michalik L: PPARs at the
crossroads of lipid signaling and inflammation. Trends Endocrinol
Metab. 23:351–363. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Salvado L, Barroso E, Gomez-Foix AM,
Palomer X, Michalik L, Wahli W and Vázquez-Carrera M:
PPARbeta/delta prevents endoplasmic reticulum stress-associated
inflammation and insulin resistance in skeletal muscle cells
through an AMPK-dependent mechanism. Diabetologia. 57:2126–2135.
2014. View Article : Google Scholar
|
|
44
|
Palomer X, Capdevila-Busquets E, Botteri
G, Salvadó L, Barroso E, Davidson MM, Michalik L, Wahli W and
Vázquez-Carrera M: PPARbeta/delta attenuates palmitate-induced
endoplasmic reticulum stress and induces autophagic markers in
human cardiac cells. Int J Cardiol. 174:110–118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ding H, Zhang Y, Liu L, Yuan H, Qu J and
Shen R: Activation of peroxisome proliferator activator receptor
delta in mouse impacts lipid composition and placental development
at early stage of gestation. Biol Reprod. 91:572014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cao M, Long Y, Tong Y, Wan J and Tong N:
Activation of PPARdelta up-regulates the expression of insulin gene
transcription factor MafA and ameliorates glucose-induced insulin
secretion impaired by palmitate. Mol Cell Biochem. 366:183–189.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vacca M, D'Amore S, Graziano G, D'Orazio
A, Cariello M, Massafra V, Salvatore L, Martelli N, Murzilli S, Lo
Sasso G, et al: Clustering nuclear receptors in liver regeneration
identifies candidate modulators of hepatocyte proliferation and
hepatocarcinoma. PLoS One. 9:e1044492014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kostadinova R, Montagner A, Gouranton E,
Fleury S, Guillou H, Dombrowicz D, Desreumaux P and Wahli W:
GW501516-activated PPARbeta/delta promotes liver fibrosis via
p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell
Biosci. 2:342012. View Article : Google Scholar
|
|
49
|
Wang J, Xu F, Zhu D, Duan Y, Chen J, Sun
X, He X, Li P, Sun W and Feng J: Schistosoma japonicum soluble egg
antigens facilitate hepatic stellate cell apoptosis by
downregulating Akt expression and upregulating p53 and DR5
expression. PLoS Negl Trop Dis. 8:e31062014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Iwaisako K, Haimerl M, Paik YH, Taura K,
Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, et al:
Protection from liver fibrosis by a peroxisome
proliferator-activated receptor delta agonist. Proc Natl Acad Sci
USA. 109:E1369–E1376. 2012. View Article : Google Scholar
|
|
51
|
Feng YZ, Nikolic N, Bakke SS, Boekschoten
MV, Kersten S, Kase ET, Rustan AC and Thoresen GH: PPARdelta
activation in human myotubes increases mitochondrial fatty acid
oxidative capacity and reduces glucose utilization by a switch in
substrate preference. Arch Physiol Biochem. 120:12–21. 2014.
View Article : Google Scholar
|
|
52
|
Oliver WR Jr, Shenk JL, Snaith MR, Russell
CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML,
Lambert MH, et al: A selective peroxisome proliferator-activated
receptor delta agonist promotes reverse cholesterol transport. Proc
Natl Acad Sci USA. 98:5306–5311. 2001. View Article : Google Scholar : PubMed/NCBI
|
